Sherali Afroze Ramzan, Moorani Khemchand N, Chishty Saeed Hassan, Khan Shuja Iqbal
Department of Paediatric Nephrology, National Institute of Child Health (NICH), Karachi.
J Coll Physicians Surg Pak. 2014 Feb;24(2):110-3.
To determine whether Zinc supplementation could reduce relapse rate in children with nephrotic syndrome.
Randomized-controlled trial.
National Institute of Child-Health and The Kidney Centre, Karachi, from January 2008 to June 2009.
Sixty nephrotic children aged 2 - 15 years were selected. Baseline data including age, number of infections and relapses during pre and post study one year were recorded. Randomization was done to divide into Zinc group (Zg) to receive Zinc versus placebo (Pg) for 6 months. Relapses and infections were treated with standard therapy. T-test and chi-square tests were used to compare the mean values and proportions respectively with significance at p < 0.05.
Among 60 children, 54 completed trial (Zg = 25, Pg = 29). Forty (74%) were males and 14 (26%) females. Mean age, pre study relapses and Zinc level in the two groups were similar. Overall, infections and relapses were observed in 43 (79.62%) and 17 cases (31.48%) respectively. There was no significant difference in frequency of infections and mean infection rate in Zg (20, 80% and 1.92 ± 1.47) compared to Pg (23, 79.3% and 2 ± 1.53, p = 0.950). Relapses occurred in 7 (28%) in Zg compared to 10 (34%) in Pg which was not significant (p = 0.609). Mean infection and relapse rate per patient per year (PPPY) in Zg was 1.92 ± 1.47and 1.14 ± 0.37 compared to 2 ± 1.53 and1.3 ± 0.48 in Pg respectively (p=0.846, 0.464). Pre study relapses in two groups were similar (Zg vs. Pg = 96 vs. 96.6%) whereas post study relapses in Zg were lower (7, 28%) compared to Pg (10, 34.5%). Post study mean relapse rate in Zg was 1.14 ± 0.37 PPPY compared to 2.71 ± 1.11 in pre study (p = 0.005). In Pg, post study mean relapse rate PPPY was 1.30 ± 0.48 compared to 1.70 ± 0.48 in pre study period (p = 0.037). Relapse rate reduction was 43% after Zinc supplementation compared to 27% reduction in placebo. Metallic taste was observed in 10% of cases.
Zinc supplementation was helpful in reducing relapses in nephrotic syndrome.
确定补充锌是否能降低肾病综合征患儿的复发率。
随机对照试验。
2008年1月至2009年6月，位于卡拉奇的国家儿童健康与肾脏中心。
选取60名2至15岁的肾病患儿。记录基线数据，包括年龄、研究前一年和研究后一年的感染次数及复发次数。进行随机分组，分为锌组（Zg）接受锌治疗和安慰剂组（Pg），为期6个月。复发和感染采用标准疗法治疗。采用t检验和卡方检验分别比较均值和比例，p<0.05具有显著性。
60名儿童中，54名完成试验（Zg=25，Pg=29）。40名（74%）为男性，14名（26%）为女性。两组的平均年龄、研究前复发情况和锌水平相似。总体而言，分别有43例（79.62%）和17例（31.48%）观察到感染和复发。与Pg组（23例，79.3%，感染率2±1.53）相比，Zg组的感染频率和平均感染率（20例，80%，感染率1.92±1.47）无显著差异（p=0.950）。Zg组7例（28%）复发，Pg组10例（34%）复发，差异不显著（p=0.609）。Zg组每名患者每年的平均感染率和复发率分别为1.92±1.47和1.14±0.37，而Pg组分别为2±1.53和1.3±0.48（p=0.846，0.464）。两组研究前的复发情况相似（Zg组与Pg组分别为96次与96.6%），而研究后Zg组的复发率较低（7例，28%），低于Pg组（10例，34.5%）。Zg组研究后的平均复发率为每名患者每年1.14±0.37，而研究前为2.71±1.11（p=0.005）。在Pg组，研究后的平均复发率为每名患者每年1.30±0.48，而研究前期为1.70±0.48（p=0.037）。补充锌后复发率降低了43%，而安慰剂组降低了27%。10%的病例出现金属味。
补充锌有助于降低肾病综合征的复发率。
Zotero 插件